第九届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第十一 次会议于 2025 年 8 月 15 日以电子发送等形式发出会议通知，会议于 2025 年 8 月 28 日上午 9:30 以通讯方式召开。应出席本次会议的董事为 9 名，实际出席会议的 董事为 9 名。会议由公司董事长俞熔先生主持，公司监事及高级管理人员列席了 会议。本次会议的出席人数、召开表决程序、议事内容均符合《中华人民共和国 公司法》《公司章程》等有关规定。 证券代码：002044 证券简称：美年健康 公告编号：2025-059 二、董事会会议审议情况 1、审议并通过《公司 2025 年半年度报告及其摘要》 美年大健康产业控股股份有限公司 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 公司董事会审计委员会审议通过了该议案。 《公司 2025 年半年度报告》全文详见公司指定信息披露媒体巨潮资讯网 （www.cninfo.com.cn），《公司 2025 年半年度报告摘要》详 ...

美年大健康产业控股股份有限公司 2025 年半年度报告全文 美年大健康产业控股股份有限公司 2025 年半年度报告 2025 年 08 月 1 美年大健康产业控股股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人俞熔、主管会计工作负责人侯灵昌及会计机构负责人（会计 主管人员）侯灵昌声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及的未来计划等前瞻性陈述不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计 划、预测与承诺之间的差异。 公司不存在经营状况、财务状况和持续盈利能力方面有严重不利影响的 风险因素。有关公司可能面临的风险及公司应对措施等详见本报告"第三节 管理层讨论与分析"中"十、公司面临的风险和应对措施"，敬请投资者认真阅 读并注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 ...

Group 1 - The Alzheimer's concept sector declined by 1.07%, ranking among the top declines in the concept sector, with companies like Jingxin Pharmaceutical, Kanghong Pharmaceutical, and Meinian Health showing significant drops [1][2] - Among the Alzheimer's concept stocks, five stocks experienced price increases, with Tonghua Golden Horse, Wangsu Technology, and United Imaging Healthcare rising by 2.02%, 1.48%, and 0.49% respectively [1][2] - The sector saw a net outflow of 1.073 billion yuan from major funds, with 32 stocks experiencing outflows, and 11 stocks seeing outflows exceeding 30 million yuan [2][3] Group 2 - The top net outflow stocks in the Alzheimer's concept included Wangsu Technology with a net outflow of 233.89 million yuan, Meinian Health with 164.59 million yuan, and United Imaging Healthcare with 94.36 million yuan [2][3] - The stocks with the highest net inflows included Daan Diagnostics and Baiyang Pharmaceutical, with net inflows of 2.80 million yuan and 1.30 million yuan respectively [2][3] - The trading volume for the Alzheimer's concept stocks showed significant turnover rates, with Wangsu Technology at 7.68% and Meinian Health at 4.58% [2][3]

Group 1 - The core point of the news is that Meinian Health experienced a decline in stock price, dropping by 5.15% to 5.52 CNY per share, with a trading volume of 705 million CNY and a turnover rate of 3.20%, resulting in a total market capitalization of 21.607 billion CNY [1] - Meinian Health primarily engages in health check-ups and health management services, with 96.53% of its revenue coming from health check-up services and 3.47% from other services [1] Group 2 - From the perspective of fund holdings, Huatai-PB Fund has one fund heavily invested in Meinian Health, specifically the Health ETF (516790), which reduced its holdings by 20,000 shares in the second quarter, now holding 460,600 shares, accounting for 2.11% of the fund's net value, ranking as the ninth largest holding [2] - The Health ETF (516790) was established on August 12, 2021, with a current size of 112 million CNY, showing a year-to-date return of 13.68% and a one-year return of 33.79%, ranking 2866 out of 4222 and 2534 out of 3776 respectively, while it has incurred a loss of 35.7% since inception [2]

Market Overview - The medical services sector experienced a decline of 2.4% on August 26, with Sunlight Nuohe leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Individual Stock Performance - Notable gainers included Tongce Medical, which rose by 2.38% to a closing price of 48.26, and Lanwei Medical, which increased by 0.66% to 10.66 [1] - Conversely, Sunlight Nuohe saw a significant decline of 9.88%, closing at 72.10, while Hite Bio fell by 7.32% to 55.06 [2] Trading Volume and Capital Flow - The medical services sector saw a net outflow of 2.199 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.11 billion yuan [2][3] - The trading volume for key stocks varied, with Aier Eye Hospital recording a significant outflow of 859.905 million yuan from institutional investors [3] Summary of Key Stocks - Aier Eye Hospital: Closing price 13.83, down 0.58%, with a trading volume of 1.3036 million shares [1] - Sunlight Nuohe: Closing price 72.10, down 9.88%, with a trading volume of 81,300 shares [2] - Hite Bio: Closing price 55.06, down 7.32%, with a trading volume of 145,600 shares [2]

Core Viewpoint - The CSI All Share Healthcare Equipment and Services Index has shown significant growth, reflecting a positive trend in the healthcare sector, with a notable increase in trading volume and index performance over various time frames [1][2]. Group 1: Index Performance - The CSI All Share Healthcare Equipment and Services Index rose by 0.14% to 15,554.17 points, with a trading volume of 35.351 billion [1]. - Over the past month, the index has increased by 10.85%, by 14.71% over the last three months, and by 13.47% year-to-date [1]. Group 2: Index Composition - The index comprises companies related to the healthcare theme, with the top ten weighted companies being Mindray Medical (9.17%), United Imaging (7.63%), Aier Eye Hospital (7.12%), and others [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (59.89%) and the Shanghai Stock Exchange (40.11%) [1]. Group 3: Industry Representation - The index exclusively represents the healthcare sector, with a 100% allocation to pharmaceutical and healthcare-related companies [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. Group 4: Investment Products - Several public funds track the CSI All Share Healthcare Equipment and Services Index, including various Southern and Tianhong funds, as well as ETFs from different asset management companies [2].

Core Viewpoint - The private health examination industry is facing significant challenges despite rising prices, with major players like Meinian Health experiencing declining revenues and increasing losses [3][5]. Group 1: Industry Overview - The private health examination sector has expanded rapidly since 2010, primarily driven by capital investment, with about 80% of business coming from corporate clients [3][4]. - The market size of China's health examination industry is nearing 300 billion yuan in 2023, with public hospitals holding a 70% market share, leaving private institutions like Meinian Health with just over 20% [5][6]. Group 2: Financial Performance - Meinian Health reported a revenue decline and a loss of approximately 200 million yuan in the first half of the year, continuing a trend of decreasing income and profits over the past two years [3][4]. - The average customer spending at examination centers is rising, yet the overall financial performance of leading private institutions is deteriorating [3][4]. Group 3: Operational Challenges - Strict regulations from health authorities regarding staffing and facility requirements impose significant operational costs, with personnel expenses accounting for about 30% of operating costs [4][6]. - The need for advanced medical equipment and the high costs associated with maintaining large facilities contribute to financial strain, as investments in a 2000-3000 square meter center can reach around 20 million yuan [4][6]. Group 4: Market Dynamics - Corporate clients, while providing a large volume of business, possess strong bargaining power, leading to challenges in pricing and profitability for examination institutions [7]. - In response to stagnation in corporate client growth, Meinian Health is shifting focus towards individual clients, which typically yield higher profit margins [7][8]. Group 5: Marketing and Pricing Strategies - To attract individual clients, examination institutions are investing heavily in marketing, with Meinian Health's sales expenses exceeding 2.5 billion yuan in 2024 [7]. - The introduction of various health examination packages on e-commerce platforms has led to price increases, driven by internal adjustments and external costs from third-party platforms [7][8].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Meinian Health, indicating a significant premium in its price-to-earnings (PE) ratio compared to the industry average [1][2] - As of August 22, Meinian Health's closing price was 5.82 yuan, with a PE ratio of 77.61, which is substantially higher than the industry average PE of 49.39 [1][2] - The company's total market capitalization stands at 22.781 billion yuan, ranking it 36th in the healthcare services sector [1][2] Group 2 - In terms of capital flow, Meinian Health experienced a net inflow of 32.5573 million yuan on August 22, with a total inflow of 356.5616 million yuan over the past five days [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 1.754 billion yuan, reflecting a year-on-year decrease of 2.62%, while the net profit was a loss of approximately 275.34 million yuan, with a year-on-year increase of 3.94% [1] - The gross profit margin for the company is reported at 24.04% [1]

金融界消息 截至2025年8月22日收盘，美年健康（002044）报收于5.82元，上涨1.57%，换手率2.83%， 成交量109.66万手，成交金额6.35亿元。 资金流向方面，今日主力资金净流入3255.73万元，占比成交额5.13%。其中，超大单净流入3574.01万 元、占成交额5.63%，大单净流出318.28万元、占成交额0.5%，中单净流出流出2772.56万元、占成交额 4.37%，小单净流出483.17万元、占成交额0.76%。 美年健康最新一期业绩显示，截至2025一季报，公司营业总收入17.54亿元、同比减少2.62%，归属净利 润27533.81万元，同比增长3.94%，扣非净利润28232.27万元，同比增长6.52%，流动比率0.725、速动比 率0.703、资产负债率56.34%。 天眼查商业履历信息显示，美年大健康产业控股股份有限公司，成立于1991年，位于绍兴市，是一家以 从事研究和试验发展为主的企业。企业注册资本391425.3923万人民币，实缴资本8000万人民币。公司 法定代表人为俞熔。 通过天眼查大数据分析，美年大健康产业控股股份有限公司共对外投资了37家企业，参 ...

资金流向方面，8月21日主力资金净流入1234.61万元，近五日主力资金累计净流入4.16亿元，显示市场 对该股的关注度较高。 风险提示：行业竞争加剧、技术研发不及预期、政策变化等因素可能对公司经营产生影响。 截至2025年8月21日15时，美年健康股价报5.73元，较前一交易日下跌2.39%。当日成交额达7.28亿元， 换手率为3.25%。 美年健康是国内领先的体检及健康管理服务提供商，专注于预防医学领域。公司近年来大力推动AI技 术在健康管理全流程的应用，包括检前个性化套餐生成、检中AI辅助诊断及检后健康追踪服务。 消息面上，美年健康近期持续推进AI健康管理技术的商业化落地。公司推出的私人AI健康管理师"健康 小美"已覆盖109家体检中心，累计生成超39万份体检报告。此外，公司通过"1+X"个体化体检模式，结 合AI技术提升筛查精准度，2023年至2025年7月累计检出癌症确诊26.28万例，其中大部分为早期病例。 ...